O’Shea, Christopher
Holmes, Andrew P.
Yu, Ting Y.
Winter, James http://orcid.org/0000-0002-6923-7597
Wells, Simon P.
Correia, Joao
Boukens, Bastiaan J.
De Groot, Joris R.
Chu, Gavin S.
Li, Xin
Ng, G. Andre http://orcid.org/0000-0001-5965-0671
Kirchhof, Paulus
Fabritz, Larissa http://orcid.org/0000-0002-9241-1733
Rajpoot, Kashif
Pavlovic, Davor http://orcid.org/0000-0002-3171-3551
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (L016346)
Wellcome Trust (109604/Z/15/Z)
British Heart Foundation (RG/17/15/33106, FS/13/43/30324, PG/17/30/32961, FS/16/35/31952)
Article History
Received: 6 September 2018
Accepted: 21 December 2018
First Online: 4 February 2019
Competing Interests
: PK receives research support from several drug and device companies active in atrial fibrillation and has received honoraria from several such companies. LF has received institutional research grants from EU, BHF, MRC, DFG and Gilead. PK and LF are listed as inventors on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). All other authors declare no potential conflict of interest.